Latest Small Cap Feast

Small Cap Feast

Small Cap Feast – 02 July 2020

Dish of the Day:

No Joiners Today


Off the Menu:

Intu Properties has left AIM following the appointment of Administrators.

PureCircle has left the Main Market following a recommended cash offer.

Ecovist a has left  the Aquis Stock Exchange following an earlier suspension.


What’s Cooking in the IPO Kitchen?

AEX Gold (TSXV:AEV) is intending to admit its shares to AIM alongside a £45m placing. The Company, led by CEO Eldur Ólafsson, has established the largest land package of gold assets in Greenland with a current portfolio of licences covering 3,356 square kilometres, in the two known gold belts in Southern Greenland, the Nanortalik and Tartoq gold belts. Nalunaq is a high-grade gold asset with an updated Inferred Mineral Resource covering 422,770 tonnes at 18.5 grams per tonne of gold, or 250,970 ounces of gold, which covers the area in and around the historical mine.  Due July.  Current mkt cap C$66.7m.


Breakfast Buffet

Mosman Oil & Gas 0.09p £0.98m (MSMN.L)

£400k placing at 0.08p. Investors are also receiving one warrant to subscribe for a further new ordinary share at an exercise price of 0.15p with a term of 12 months . The net proceeds raised from the Placing will be used towards the drilling of the Falcon well at the Champion Project in Texas.  “This placing, along with the recent Blackstone settlement will result in Mosman having cash of over AUD 1.0 million. The pending sale of the Welch Oil Field announced on 20 May 2020 and due to complete shortly, could increase this to AUD 1.4 million.”


IronRidge Resources 11.5p £46.5m (IRR.L)

IronRidge Resources reported the definition of a drill ready target at Yakassé within the Zaranou gold license in Côte d’Ivoire from recently secured historical data. Additionally, the Company is pleased to report that the second phase drilling programme currently underway has been enlarged over the Phase 1 drill area, now named the Ehuasso target , as well as a new soil anomaly to the north-east, called the Ebilassokro target ; both within the Zaranou license area. The license borders with Ghana and is along strike from significant operating gold mines including Chirano (5Moz), Bibiani (5.5Moz) and Ahafo (17Moz).


Salt Lake Potash 29.5p £104m (SO4.L)

SO4 has received commitments to raise A$15m through the placement of unsecured zero-coupon convertible notes to corporate and institutional investors. The Convertible Notes have been structured as deferred equity with zero coupon and mandatory conversion into Salt Lake ordinary shares of no par value (Shares) at the lower of 45c/Share or a 5% discount to any future equity raising of at least A$10m.

The funds will allow SO4 to continue the rapid development of Lake Way as construction activities ramp-up through July. Plant practical completion and first SOP sales remain on schedule for the March 2021 quarter.

The Company is in the final stages of completing the debt financing that is required to deliver project financial close at Lake Way. A final agreement is expected to be executed within weeks.


Omega Diagnostics 41.5p £65.6m (ODX.L)

The medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that its CE-Marked Mologic ELISA1 antibody test has been approved for testing of COVID-19 in India. 

Yesterday the Central Drugs Standard Control Organization, part of the Ministry of Health & Family Welfare, published a list of approved Rapid / CLIA / ELISA kits approved for testing of COVID-19, which included Omega’s ELISA antibody test.

Approval for sale remains conditional on the submission of supporting technical data and the Company is confident that this submission will be successful, and that Omega will be able to sell its ELISA antibody test directly into this potentially significant target market.


Gamma Communications 1350p £1.2b (GAMA.L)

Gamma has acquired c80% of the issued share capital of HFO Holding AG  on 1 July 2020 for 20.4m (and has an option to acquire the remaining c20% over the next three years).  HFO is one of the leading SIP Trunk providers in Germany with an excellent reputation for product quality and end-customer service.  It has a strategy to build on this expertise in both the VOIP and broad business communications markets, and has recently started to sell Cloud PBX offerings through its extensive network of channel partners across the German market.

As part of its stated European expansion strategy, Gamma had previously identified Germany as a key target geography. With an overall market of c.36 million PBX seats (almost twice the UK market size) but a cloud penetration of only c6% (one of the lowest rates in Western Europe), the German market for cloud telephony is forecast to grow rapidly. For the year ended 31 December 2019, HFO had revenues of 45.9m, operating profits (adjusted EBITDA) of 3.2m and at 31 December 2019 had net assets of 4.6m. 


Verditek 9.15p £26.7m (VDTK.L)

The clean technology company is pleased to announce, following its successful product development activities, that it has received a number of orders over the past two weeks in new geographical areas and new vertical markets .

The team has successfully secured its first order for the very profitable marine market, selling panels in Thailand to be used on yachts.  The lightweight solar panels provided will be used to power the cabin electrical loads such as navigation, lighting. and communication equipment.  In the UK, Verditek has secured its first order in the agricultural sector, with Verditek solar panels to be installed on the roofs of barns in the near future.  Due to the low load bearing characteristics of these structures the installation of a lightweight solar panels on the roof was the only practical solution to generating electricity.  Following on from the success in Pakistan, Verditek has secured another order in the Oil & Gas vertical.


CREO Medical 212p £334m (CREO.L)

The medical device company focused on the emerging field of surgical endoscopy, announces that the Group has secured a £2m loan from the Cardiff Capital Region (“CCR”) to develop Creo’s Cool Plasma technology as a method to kill bacteria and viruses and for sterilisation purposes. Creo’s technology has both medical and non-medical applications and initial testing has demonstrated that it can be effective for COVID-19 inactivation and decontamination. The Company believes that the technology has the potential for use in wound care, medical device sterilisation, PPE sterilisation, endoscope sterilisation to kill the bacteria associated with urinary tract infections, as well as general sterilisation and cleaning of enclosed environments within the service and transport sectors.


4d Pharma 40.7p £44.6m (DDDD.L)

The pharmaceutical company leading the development of Live Biotherapeutics, today announces that its Phase II clinical trial of oral immunomodulator MRx-4DP0004 for patients hospitalised with COVID-19 is now open to enrolment, and dosing of the first patients is expected shortly. 

The Phase II randomized, double-blind, placebo-controlled trial is enrolling up to 90 patients admitted to hospital with COVID-19 in the UK. Eligible patients will receive daily oral MRx-4DP0004 or placebo, in addition to standard supportive care.  The primary endpoint of the trial is the mean change in clinical status score as measured by the WHO Ordinal Scale for Clinical Improvement. In addition, a number of secondary endpoints assess measures of clinical efficacy including the need for, and duration of, ventilation, in addition to safety and tolerability.


OnTheMarket 85p £60.7m (OTMP.L)

The majority agent-owned company which operates the property portal, announces that almost 500 estate agent branches are now contracted under the Company’s most recent listing offers, which issue welcome shares to each business owner.   Of the branches signing up to the new listing agreements, more than 60% are currently contracted to either list exclusively with OnTheMarket or on a one other portal basis of either Rightmove or Zoopla/Primelocation.

Launched on 27 April 2020, the new contracts issue either £1,000 of welcome shares per office with flexible portal choices, or £2,500 of welcome shares per office if an agent commits to list exclusively for a minimum of 12 months.

Following the announcement on 23 June 2020, OnTheMarket has continued to set new records with the number of leads it delivered to advertisers in June 2020.

More than 1.8 million leads were generated in the month, with an average of 134 leads per advertiser.


Reabold Resources 0.57p £38.5m (RBD.L)

Update on well flow test operations at the Iecea Mica-1 well in Romania as part of the 2020 work programme.

The Work Programme is being carried out by Danube Petroleum Limited, which has a 100 per cent. interest in the Parta Sole Risk Area and will, on completion of the farmout to Tamaska Oil & Gas have a 50 per cent. interest in the Parta Exploration Licence.

Reabold holds a 50.8 per cent. equity interest in Danube. ADX Energy Ltd is the operator of IMIC-1.

Highlights :

  • Well production equipment has been run into the IMIC-1 well which has been perforated to initiate flow from the Lower Pannonian Pa IV gas reservoir

o  The PaV and Pa III potential gas reservoirs were not perforated during the current operations

  • Mud filtrate build-up around the well bore has potentially occurred; following further diagnostic work, acidization of the well may be implemented to enhance flow

o  Reservoir acidization may be required to break down mud filter cake which builds up around the well bore and is relatively common practice in the region

o  Cuttings from IMIC-1 drilling analysis together with modern petrophysical analysis of the newly acquired IMIC-1 logs indicated good Pa IV gas reservoir permeability

  • The programme will be ongoing over the coming weeks including down hole pressure measurement, fluid sampling and future stimulation or further testing programmes
  • Further down hole pressure measurement and sampling of reservoir fluids work will be undertaken utilising low-cost wire line equipment following rig demobilisation


Head Chef:

Derren Nathan
0203 764 2344

*A corporate client of Hybridan LLP


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.